Celator Pharmaceuticals Selected to Participate in NCI’s Nanotechnology Characterization Laboratory Assay Cascade for Characterization of Nanoparticle Prodrug Delivery Platform

Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

Related Posts

Comments are closed.